Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Inhalers are crucial tools for people with lung conditions such as asthma or chronic obstructive pulmonary disease (COPD ... and not the inhaler canister, tt's best to hold on to the packaging ...

AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...

The purpose of selecting an appropriate inhaler device is to improve patient adherence and inhaler technique to achieve the goals of therapy for patients with COPD. In 2005, the American College ...

GSK, leading the COPD market with its Trelegy ... therapies should not overshadow choosing the best therapy for each patient. "Are dry powder inhalers the key to sustainable respiratory care?" ...

Qualcomm and its rival Propeller are emerging as the tech companies to partner with in the development of smart inhalers. Virtually all the companies active in the asthma and COPD markets have ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).